Your browser doesn't support javascript.
loading
A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.
Benoit, Anita C; Younger, Jaime; Beaver, Kerrigan; Jackson, Randy; Loutfy, Mona; Masching, Renée; Nobis, Tony; Nowgesic, Earl; O'Brien-Teengs, Doe; Whitebird, Wanda; Zoccole, Art; Hull, Mark; Jaworsky, Denise; Rachlis, Anita; Rourke, Sean; Burchell, Ann N; Cooper, Curtis; Hogg, Robert; Klein, Marina B; Machouf, Nima; Montaner, Julio; Tsoukas, Chris; Raboud, Janet.
Afiliación
  • Benoit AC; Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
  • Younger J; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Beaver K; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Jackson R; Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
  • Loutfy M; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Masching R; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Nobis T; McMaster University, Hamilton, ON, Canada.
  • Nowgesic E; Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
  • O'Brien-Teengs D; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Whitebird W; Maple Leaf Medical Clinic, Toronto, ON, Canada.
  • Zoccole A; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Hull M; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Jaworsky D; Canadian Aboriginal AIDS Network, Dartmouth, NS, Canada.
  • Rachlis A; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Rourke S; Ontario Aboriginal HIV/AIDS Strategy, Toronto, ON, Canada.
  • Burchell AN; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Cooper C; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Hogg R; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Klein MB; Lakehead University, Thunder Bay, ON, Canada.
  • Machouf N; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Montaner J; Ontario Aboriginal HIV/AIDS Strategy, Toronto, ON, Canada.
  • Tsoukas C; Building Bridges Team, Toronto, ON & Vancouver, BC, Canada.
  • Raboud J; 2-Spirited People of the 1st Nations, Toronto, ON, Canada.
Antivir Ther ; 22(4): 325-335, 2017.
Article en En | MEDLINE | ID: mdl-27925609
ABSTRACT

BACKGROUND:

This study compared time to virological suppression and rebound between Indigenous and non-Indigenous individuals living with HIV in Canada initiating combination antiretroviral therapy (cART).

METHODS:

Data were from the Canadian Observational Cohort collaboration; eight studies of treatment-naive persons with HIV initiating cART after 1/1/2000. Fine and Gray models were used to estimate the effect of ethnicity on time to virological suppression (two consecutive viral loads [VLs] <50 copies/ml at least 3 months apart) after adjusting for the competing risk of death and time until virological rebound (two consecutive VLs >200 copies/ml at least 3 months apart) following suppression.

RESULTS:

Among 7,080 participants were 497 Indigenous persons of whom 413 (83%) were from British Columbia. The cumulative incidence of suppression 1 year after cART initiation was 54% for Indigenous persons, 77% for Caucasian and 80% for African, Caribbean or Black (ACB) persons. The cumulative incidence of rebound 1 year after suppression was 13% for Indigenous persons, 6% for Caucasian and 7% for ACB persons. Indigenous persons were less likely to achieve suppression than Caucasian participants (aHR=0.58, 95% CI 0.50, 0.68), but not more likely to experience rebound (aHR=1.03, 95% CI 0.84, 1.27) after adjusting for age, gender, injection drug use, men having sex with men status, province of residence, baseline VL and CD4+ T-cell count, antiretroviral class and year of cART initiation.

CONCLUSIONS:

Lower suppression rates among Indigenous persons suggest a need for targeted interventions to improve HIV health outcomes during the first year of treatment when suppression is usually achieved.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH / Fármacos Anti-VIH / Carga Viral Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Antivir Ther Asunto de la revista: TERAPIA POR MEDICAMENTOS / VIROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH / Fármacos Anti-VIH / Carga Viral Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Antivir Ther Asunto de la revista: TERAPIA POR MEDICAMENTOS / VIROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Canadá